-
Reflecting on #BlackFamCan Week and the aftermath of declines in screenings
This summer, the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) launched its inaugural National Black Family Cancer Awareness Week, an important ... Read More -
Diseases are smart, so labs stay smarter: chasing evolving diseases in the lab
From a young age, Shrei Crenshaw was destined for a career in health care. She was passionate about helping others, but saw herself being more ... Read More -
“Striving to find that answer”: At BioReference and GeneDx, lab professionals put their hearts into all that they do
Delivering answers for patients isn’t just a job, it’s a calling. For Katie Aoyama, the Assistant Director of the Technology, Transfer and Validation Department at ... Read More -
ACLA Statement on Reintroduction of the VALID Act
Washington, D.C. – Following the reintroduction of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, ACLA President Julie Khani issued the following statement: ... Read More -
ACLA Statement on MedPAC Report
WASHINGTON, D.C.— Following the release of MedPAC’s June report, ACLA President Julie Khani issued the following statement: “Recognizing the flawed implementation of the 2014 Protecting Access to ... Read More -
ACLA Files Notice of Appeal in ACLA v. Becerra
Washington, D.C. – The American Clinical Laboratory Association (ACLA) today filed a notice of appeal in its lawsuit against the U.S. Department of Health and Human ... Read More -
ACLA v. Becerra: Frequently Asked Questions
What is ACLA’s response to the court’s recent dismissal of the lawsuit? On March 30, 2021, the district court for the District of Columbia issued ... Read More -
ACLA Applauds New Investments in COVID-19 Testing for the Uninsured
WASHINGTON, D.C. – Following today’s announcement by the US Department of Health and Human Services (HHS) that it is dedicating $4.8 billion from the American Rescue Plan (ARP) to ... Read More -
ACLA Letter to Secretary Becerra on the Regulation of Laboratory Developed Tests (LDTs)
-
ACLA Comment Letter on 2021 NCCI Policy Manual
